Treatment of severe hypertension with intravenous labetalol

Publisher Website
Google Scholar
Abstract
The effectiveness of repeated i.v. injections of labetolol in reducing blood pressure (BP) was evaluated at in patients with severe hypertension. The subjects were 10 patients who were 29-61 yr old and who had diastolic blood pressure (DBP) of .gtoreq. 125 mm Hg. Repeated injections titrated from 20-80 mg were given at 15-min intervals until there was a reduction in DBP of 30 mm Hg or until 300 mg had been administered. The average reduction of BP ranged from 201 .+-. 5/132 .+-. 1 to 157 .+-. 6/108 .+-. 4 mm Hg (mean .+-. SEM [standard error of the mean]). Four patients responded with a reduction in DBP of .gtoreq. 30 mm Hg with total doses of 60-220 mg. Of the remaining 6 who received the full dose, in 4 there was a 20- to 29-mm Hg reduction in DBP, in 1 there was a 10-mm Hg fall, and in 1 there was no reduction. There was a positive correlation between age and response to i.v. labetolol. There was a positive correlation between age and response to i.v. labetolol. No severe side effects were encountered. Labetolol i.v. is useful and well tolerated in patients with severe hypertension.

This publication has 1 reference indexed in Scilit: